SGMT vs SLDB

Sagimet Biosciences Inc. - Seri vs Solid Biosciences Inc. — Valuation Comparison 2026

SGMT

Biotechnology
Sagimet Biosciences Inc. - Seri
Quality
3.8
out of 10
Value Trap
24
SAFE
Price
$7.27
Last close
Models
7/13
Active
VS

SLDB

Biotechnology
Solid Biosciences Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$7.07
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SGMT Fair ValueSGMT Upside SLDB Fair ValueSLDB Upside
Bayesian DCF Intrinsic $2.28 -68.7% $3.47 -50.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.92 -87.4% $0.21 -97.1%
Dynamic NAV Asset-Based $1.96 -73.0% $4.75 -32.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SGMT vs SLDB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SGMT vs SLDB — Which Stock Is More Undervalued?

SLDB scores higher with a 4.4/10 quality rating vs SGMT's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sagimet Biosciences Inc. - Seri (SGMT) and Solid Biosciences Inc. (SLDB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SGMT currently trades at $7.27 with a QOC of 3.8/10, while SLDB trades at $7.07 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).